Compare Torrent Pharma with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs LUPIN - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA LUPIN TORRENT PHARMA/
LUPIN
 
P/E (TTM) x 36.5 41.7 87.5% View Chart
P/BV x 9.2 3.8 240.9% View Chart
Dividend Yield % 0.7 0.6 116.7%  

Financials

 TORRENT PHARMA   LUPIN
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
LUPIN
Mar-20
TORRENT PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,964882 222.6%   
Low Rs1,245505 246.5%   
Sales per share (Unadj.) Rs453.4339.4 133.6%  
Earnings per share (Unadj.) Rs25.8-5.9 -433.6%  
Cash flow per share (Unadj.) Rs62.315.5 402.6%  
Dividends per share (Unadj.) Rs17.006.00 283.3%  
Dividend yield (eoy) %1.10.9 122.5%  
Book value per share (Unadj.) Rs279.2276.7 100.9%  
Shares outstanding (eoy) m169.22453.00 37.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.52.0 173.2%   
Avg P/E ratio x62.2-116.6 -53.4%  
P/CF ratio (eoy) x25.844.8 57.5%  
Price / Book Value ratio x5.72.5 229.3%  
Dividend payout %65.9-100.9 -65.3%   
Avg Mkt Cap Rs m271,513314,201 86.4%   
No. of employees `00013.618.3 74.3%   
Total wages/salary Rs m14,03829,868 47.0%   
Avg. sales/employee Rs Th5,642.68,400.6 67.2%   
Avg. wages/employee Rs Th1,032.41,632.0 63.3%   
Avg. net profit/employee Rs Th320.9-147.2 -218.0%   
INCOME DATA
Net Sales Rs m76,728153,748 49.9%  
Other income Rs m5714,838 11.8%   
Total revenues Rs m77,299158,585 48.7%   
Gross profit Rs m19,83124,849 79.8%  
Depreciation Rs m6,1779,702 63.7%   
Interest Rs m5,0383,630 138.8%   
Profit before tax Rs m9,18716,355 56.2%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m-3,570-7,521 47.5%   
Tax Rs m1,25411,571 10.8%   
Profit after tax Rs m4,363-2,694 -162.0%  
Gross profit margin %25.816.2 159.9%  
Effective tax rate %13.670.8 19.3%   
Net profit margin %5.7-1.8 -324.5%  
BALANCE SHEET DATA
Current assets Rs m50,375154,132 32.7%   
Current liabilities Rs m51,65392,252 56.0%   
Net working cap to sales %-1.740.2 -4.1%  
Current ratio x1.01.7 58.4%  
Inventory Days Days9282 112.2%  
Debtors Days Days68129 52.8%  
Net fixed assets Rs m83,64889,082 93.9%   
Share capital Rs m846906 93.4%   
"Free" reserves Rs m46,397124,461 37.3%   
Net worth Rs m47,244125,367 37.7%   
Long term debt Rs m39,12917,933 218.2%   
Total assets Rs m141,209249,839 56.5%  
Interest coverage x2.85.5 51.3%   
Debt to equity ratio x0.80.1 579.0%  
Sales to assets ratio x0.50.6 88.3%   
Return on assets %6.70.4 1,777.1%  
Return on equity %9.2-2.1 -429.8%  
Return on capital %12.38.7 141.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,10351,450 43.0%   
Fx outflow Rs m5,52219,470 28.4%   
Net fx Rs m16,58131,980 51.8%   
CASH FLOW
From Operations Rs m17,98114,688 122.4%  
From Investments Rs m-2,41311,070 -21.8%  
From Financial Activity Rs m-13,145-8,906 147.6%  
Net Cashflow Rs m2,38016,853 14.1%  

Share Holding

Indian Promoters % 71.5 46.6 153.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.0 11.3 62.1%  
FIIs % 12.6 31.9 39.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.1 87.1%  
Shareholders   26,511 98,259 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   SHASUN PHARMA  DR. REDDYS LAB  GSK PHARMA  ALEMBIC  PROCTER & GAMBLE HEALTH  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; JSW Steel and ICICI Bank Among Top Nifty Gainers(Closing)

Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Apr 22, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS